The ‘FebBenz’ approach for severe difficult-to-treat gout
Exploration of Musculoskeletal Diseases · 2025
DOI: 10.37349/emd.2025.100793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Musculoskeletal Diseases, 2025. Verfasst von Enrique Calvo-Aranda und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
To evaluate the efficacy and tolerability of febuxostat (FBX) and benzbromarone (BNZ) combination therapy in patients with difficult-to-treat (D2T) gout.
Methods
This observational study was performed at two centers and included patients fulfilling the 2015 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) gout classification criteria, with clinical tophi and suboptimal response to standard urate-lowering therapy. A two-step treatment regimen was implemented: a 6-month dose escalation of the FBX dose followed by add-on BNZ. Demographic, clinical, and laboratory data—including cardiovascular risk factors (CVRFs), history of nephrolithiasis, liver enzymes, and estimated glomerular filtration rate (eGFR)—were recorded. Changes in serum urate (SUA) and eGFR were analyzed using paired t-tests.
Results
The study population comprised 15 patients (87% male, median age 59 years) with longstanding gout [median 15 years, range 3–31; interquartile range (IQR) 8–25]. Baseline SUA was 10.3 ± 1.7 mg/dL; mean eGFR was 63.7 ± 23.6 mL/min. CVRFs were common (hypertension, 93%; dyslipidemia, 73%: major adverse cardiovascular events, 13%; diabetes, 7%). At 12 months, SUA had decreased significantly to 2.9 ± 1.1 mg/dL (Δ = 7.4 mg/dL; p < 0.01), with FBX alone contributing to a Δ of 5.4 mg/dL and BNZ an additional Δ of 2.1 mg/dL (both p < 0.01). Tophi resolved in 60% of patients. No serious adverse events or significant changes in liver or renal function were observed. One unrelated death was recorded.
Conclusions
FBX + BNZ was effective and well-tolerated in patients with severe D2T gout, achieving a substantial reduction in SUA and clinically significant dissolution of tophi.
Zitieren
APA
Calvo-Aranda, E., Gómez-González, C. M., Pérez-Ruiz, F., & Novella-Navarro, M. (2025). The ‘FebBenz’ approach for severe difficult-to-treat gout. Exploration of Musculoskeletal Diseases. https://doi.org/10.37349/emd.2025.100793
Vancouver
Calvo-Aranda E, Gómez-González CM, Pérez-Ruiz F, Novella-Navarro M. The ‘FebBenz’ approach for severe difficult-to-treat gout. Exploration of Musculoskeletal Diseases. 2025. doi:10.37349/emd.2025.100793
BibTeX
@article{CalvoAranda2025,
author = {Calvo-Aranda, Enrique and Gómez-González, Claudia María and Pérez-Ruiz, Fernando and Novella-Navarro, Marta},
title = {The ‘FebBenz’ approach for severe difficult-to-treat gout},
journal = {Exploration of Musculoskeletal Diseases},
year = {2025},
doi = {10.37349/emd.2025.100793}
}
EUVIMED